Manuel Castaño

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

Catherine Orrell, Debbie Hagins, Elena Belonosova et al. · The Lancet HIV · 2017 · 118 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study

Rosario Palacios, María Luisa Mayorga, Carmen María González-Domenech et al. · Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2018 · 29 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Very low level viraemia and risk of virological failure in treated <scp>HIV</scp>‐1‐infected patients

Ramón Teira, Francesc Vidal, Pepa Muñoz-Sánchez et al. · HIV Medicine · 2016 · 23 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +11

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens

Luís F. López‐Cortés, Manuel Castaño, Miguel Ángel López‐Ruz et al. · PLoS ONE · 2016 · 18 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis

Francisco Orihuela, A. Rivero, Pompeyo Viciana et al. · Journal of Antimicrobial Chemotherapy · 2008 · 16 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17